HKLife has brought its proprietary chip, amplification, sample preparation, and quantitative analysis technologies together in BioRadar®. The investment opportunity is to bring this integrated platform to market, starting with ICU pneumonia.
The BioRadar® Advantage
An urgent clinical need ICU pneumonia demands fast decisions. BioRadar® brings broad pathogen detection and quantitative monitoring to the point where that information matters most.
Proprietary technologies working together EFADchip®, nIGSS, and HercuLAB® bring HKLife’s core technologies together in one integrated platform.
A working platform backed by human sample testing BioRadar® is an integrated, working platform developed using human samples from the outset. This experience has helped refine the system, strengthen its technical foundation, and build confidence for commercialization.
Scientific leadership and engineering depth Led by Professor Albert Cheung-Hoi Yu, whose research record includes 171 papers and 82 patents, the team combines molecular science, assay development, instrument engineering, and AI.
Diagnostics experience since 1999 HKLife brings outbreak-response experience from SARS to COVID-19 and commercial product experience across human health, animal health, and food testing through its three subsidiaries.
A clear commercial focus Investment supports bringing BioRadar® to market, starting with ICU pneumonia, through hospital partnerships and production readiness.
Ready to commercialize BioRadar®
With the core platform integrated, our focus is commercialization: establish BioRadar® in ICU pneumonia care, build hospital and commercial partnerships, and scale production.
Hospital partnerships
Production readiness
Market entry
Discuss the BioRadar® opportunity
Request the investor deck, meet our management team, or arrange a laboratory visit to explore the technology and commercialization opportunity.